鬼臼噻吩甙和环己亚硝脲对肺癌脑转移的预防作用  

VM-26 PLUS CCNU IN THE PTRVENTION OF BRAIN METASTASIS IN LUNG CANCER PATIENTS

作　　者：李金瀚 李黎波 康世均 

机构地区：[1]广州市第一军医大学南方医院肿瘤科

出　　处：《中华肿瘤杂志》1995年第4期314-315,共2页Chinese Journal of Oncology

摘　　要：本研究观察了化疗药物对肺癌脑转移的预防作用。试验组３４例系经病理确诊尚无脑转移的肺癌患者，采用含有鬼臼噻吩甙和环已亚硝脲的联合化疗方案，每４周为一周期，４个周期为一个疗程。观察指标包括临床症状和体征，头颅ＣＴ或ＭＲＩ检查。随访时间４～１２个月以上。对照组３４例，系经病理确诊尚无脑转移的肺癌患者，作随机抽样对照，所用的联合化疗方案不含鬼臼噻吩甙和环己亚硝脲，其用药周期、疗程、观察指标及随访期限均与试验组相同。结果表明，试验组与对照组脑转移的发生率分别为０．０％和２０．５％（Ｐ＜０．０５）。说明含有鬼臼噻吩甙和环己亚硝脲的联合化疗方案对肺癌脑转移有一定的预防作用。AbstractBrain metastasis is of frequent occurrence in patients with cancer of the lung.To ascertain ifbrain metastasis is preventable, 34 lung cancer patients without brain metastasis were treated with 4cycles of VM-26 plus CCNU at 4-week intervals. As a control for comparison , an equal number oflung cancer patients free of brain metastasis were treated with chemotherapy protocol which did notinclude VM-26 and CCNU. The patients were monitored by clinical symptoms, signs and CT or MRIscan and were followed up for 4～12 months. The results indicate that none of the VM-26 plus CC-NU-treated patients devefoped brain metastasis while brain metastasis occurred in 7(20.5%)of 34control patients. The difference was statistically significant (P<0.05).

关 键 词：肺肿瘤 药物疗法 脑肿瘤 预防 鬼臼噻吩甙 CCNU 

分 类 号：R734.205[医药卫生—肿瘤]